Cite

    Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., Jain, N., Takahashi, K., Burger, J., Estrov, Z., Borthakur, G., Pemmaraju, N., Paul, S., Cortes, J., & Kantarjian, H. M. (2020). long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer, 126(1), 67–75. http://access.bl.uk/ark:/81055/vdc_100098065247.0x00005e